Table 1.
Baseline characteristics# of the patients in the five data sources, data are mean or %
| COPDGene24 | OLIN25 | RECODE26 | ECLIPSE27 | UPLIFT28 | |
|---|---|---|---|---|---|
| N | 3,756 | 449 | 1,086 | 2,164 | 5,799 |
| Male (%) | 44 | 60 | 46 | 65 | 75 |
| Age | 64 | 63 | 68 | 63 | 64 |
| Post FEV1% predicted | 57.3 | 75.8 | 67.8 | 48.3 | 47.6 |
| GOLD stages based on FEV1 % | |||||
| Mild | 16 | 41 | 24 | 0 | 0 |
| Moderate | 41 | 53 | 53 | 44 | 46 |
| Severe | 26 | 6 | 19 | 42 | 45 |
| Very severe | 12 | 1 | 3 | 14 | 9 |
| Smoker (%) | 37 | Na | 37 | 36 | 30 |
| BMI <20 (%) | 5 | 3 | Na | 11 | 11 |
| History of cardiovascular disease (%) | 9.8 | 25 | 16 | 33 | 52 |
| SGRQ total score | 36 | Na | 36 | 50 | 46 |
| Exacerbations in the year prior to baseline | |||||
| Total exacerbations | 0.64 | 0.30 | 0.37 | 1.21 | 0.85 |
| Severe exacerbations | 0.18 | 0.02 | 0.02* | 0.22 | 0.25 |
Notes:
#
Only characteristics that were available in all or almost all databases were included in this table.
*
In 3 months.
Abbreviations: BMI, body mass index; ECLIPSE, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints; FEV1, forced expiratory volume in 1 second; GOLD, Global Initiative for chronic Obstructive Lung Disease; Na, not available; OLIN, Obstructive Lung Disease in Norrbotten; SGRQ, St George’s Respiratory Questionnaire.